Poseida Therapeutics Inc
PSTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$925.93M
Close$
$-6.30
166.3% downside
Current Fair Value
166.3% downsideOvervalued by 166.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $925.93 Million |
|---|---|
| Enterprise Value | $996.59 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.37 |
| Beta | 0.54 |
| Outstanding Shares | 97,160,467 |
Return
| Return on Equity | -68.11% |
|---|---|
| Return on Assets | -20.23% |
| Return on Invested Capital | -35.87% |
Valuation & Multiples
| P/E Ratio | -6.94 |
|---|---|
| PEG | 4.24 |
| Price to Sales | 9.5 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 6.61 |
| Enterprise Value to EBIT | -12.91 |
| Enterprise Value to Net Income | -17 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 1.38 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Poseida Therapeutics Inc
206 employees
CEO: Eric Ostertag Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. Poseida h...